191.49 0.00 (0.00%)
After hours: 6:35PM EDT
|Bid||191.38 x 800|
|Ask||193.11 x 1000|
|Day's Range||190.92 - 192.73|
|52 Week Range||163.31 - 210.19|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||15.17|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||5.80 (3.03%)|
|1y Target Est||207.33|
Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AMGN are favorable, with net inflows of $14.60 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. AMGN credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Stocks close up on Friday amid hopes the U.S. and China are making progress on a trade pact and word that Boeing is speeding up its 737 MAX fixes.
Leading biotech Amgen could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant ...
Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.
Despite many politicians, particularly declared presidential candidates, beginning to speak out against big pharma, an FDA medical adviser does not think that anything will come out of it “because Congress is owned by pharma.”
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and television host Jay Leno has partnered with Amgen to motivate patients and caregivers to get in the driver's seat as it relates to their cholesterol management.
On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.
Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Financial performance in fiscal 2018 In fiscal 2018, Amgen’s (AMGN) revenue rose 4% YoY (year-over-year) to $23.75 billion, and its non-GAAP EPS rose 14% YoY to $14.40. In
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
THOUSAND OAKS, Calif. , March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39 th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019 , in Boston ...
Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Capital expenditureAmgen (AMGN) and Merck (MRK) reported capital expenditure of $738 million and $2.61 billion, respectively, in fiscal 2018. In its fourth-quarter conference
Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Dividend projections Amgen (AMGN) and Merck (MRK) reported dividends per share of $5.28 and $1.99, respectively, in fiscal 2018. In its fourth-quarter conference call, Amgen
Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter conference call, Amgen (AMGN) guided for its operating expenses being flat or lower YoY (year-over-year) in fiscal
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1 as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts to be presented include real-world evidence (RWE) findings from the GOULD registry demonstrating suboptimal care for high-risk cardiovascular disease (CVD) patients.2,3 These analyses will be featured at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, March 16-18, 2019. "The findings we are presenting at ACC.19 further reinforce the growing body of evidence demonstrating how Repatha can safely and effectively lower LDL-C levels in a wide range of patients, such as those with atherosclerotic disease or who have a genetic risk of high cholesterol," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.